Patient Management of Depression Through Technology: a Study of Digitally Enabled Engagement

Not Applicable

Completed

Brief Summary: The current randomized controlled trial is a pilot study that will assess the effectiveness and feasibility of a mobile phone application intervention. The objective is to determine whether the use of a mobile health application for patient self-management of depression improves patient-provider engagement for patients diagnosed with major depressive disorder.

Detailed Description: This pilot study will be a randomized, real-world effectiveness study. Patients diagnosed with major depressive disorder starting a new prescription for an antidepressant monotherapy will be eligible for participation. The study will enroll 40 patients (20 in an observational arm of usual care and 20 with access to a mobile health application). No intervention will occur in the usual care arm. The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression. Patient reported outcomes and clinical data will be collected at baseline and at study primary endpoint (18 weeks) to assess changes over time and between groups for: patient-provider engagement, disease severity, quality of life, employment productivity, cognitive function, resource utilization, and medication adherence. Additionally, resource utilization will be assessed at the one year time point. A Student's t test, if allowed for by the data distribution, will be used to assess between group differences in patient reported outcome scales assessing patient-provider engagement.

Recruitment & Eligibility

Inclusion Criteria

Age 18 to 70
Ability to consent and participate in study (technical requirements for app: iPhone version 5 or later, active data plan or regular WiFi access)
Diagnosis with major depressive disorder
PHQ-9 score greater than 5 at baseline
Recent (0-14 days) start on monotherapy depression medication (either new prescription or a change from a previous medication)
Outpatient care provided by participating Advocate Medical Group clinics

Exclusion Criteria

Diagnosis with major psychiatric disorder (e.g. bipolar disorder, manic depressive disorder)
Contraindications to use of depression medications
Patients with treatment resistant depression [defined as patients who have not responded to two or more separate different antidepressant monotherapy trials of adequate dose and duration (6 weeks or longer) in the current depressive episode]
Considered at imminent risk for hospitalization due to severe depression in the opinion of the treating physician
History of hospitalization due to major depressive disorder in prior 3 months
Significant risk of suicide according to the treating physician's clinical judgment or previous suicide attempt in prior 6 months
History of response only to combination or augmentation therapy in current depressive episode
Receipt of any investigational compound in prior 30 days (or five half-lives, whichever is longer)
Current participation in another clinical study
Lack of functional English literacy

Arm && Interventions

Group	Intervention	Description
Mobile App	Mobile App	Standard of Care and Mobile App

Primary Outcome Measures

Name	Time	Method
Patient-provider engagement	18 weeks	This will be assessed by the Patient-Provider Engagement Scale (PPES-7), an instrument developed for this study to measure patient knowledge, communication, and interaction with their provider specific to depression management.
Patient activation	18 weeks	This will be assessed by the Patient Activation Measure, a validated scale that measures patient knowledge, skills and confidence in disease self-management in the primary care setting.

Secondary Outcome Measures

Name	Time	Method
Depression symptoms	18 weeks	This patient reported outcome is assessed by the clinical depression severity. PHQ-9 scale, which scores each of the nine DSM-IV criteria as "0" (not at all) to "3" (nearly every day).
Cognitive dysfunction	18 weeks	This patient reported outcome is assessed by the cognitive dysfunction PDQ-D scale.
Medication changes	18 weeks	This outcome will be assessed by clinical data on the frequency and types of medication switches.
WHO-5 survey	18 weeks	This patient reported outcome is assessed by the quality of life WHO-5 survey.
Health care utilization	18 weeks	This patient reported outcome is assessed by the healthcare resource utilization and cost RUQ-D survey.

Locations (1): Advocate Christ Medical Center
🇺🇸
Oak Lawn, Illinois, United States